| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $12,393,153 | 13 | 57 |
Sells | $313,428 | 10 | 43 |
| Satter Muneer A | director | 6 | $11.97M | 0 | $0 | $11.97M |
| Carson William H. | director | 5 | $180,251 | 0 | $0 | $180,251 |
| Choi Jung | director | 1 | $138,270 | 0 | $0 | $138,270 |
| Love Douglas | PRESIDENT AND CEO | 1 | $99,829 | 0 | $0 | $99,829 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 0 | $0 | 2 | $55,265 | $-55,265 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $58,582 | $-58,582 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $58,983 | $-58,983 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $70,281 | $-70,281 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 0 | $0 | 2 | $70,317 | $-70,317 |
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising …
Over the last 12 months, insiders at Annexon, Inc. have bought $12.39M and sold $313,428 worth of Annexon, Inc. stock.
On average, over the past 5 years, insiders at Annexon, Inc. have bought $6.48M and sold $225,563 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Satter Muneer A (director) — $11.97M. Carson William H. (director) — $180,251. Choi Jung (director) — $138,270.
The last purchase of 26,065 shares for transaction amount of $99,829 was made by Love Douglas (PRESIDENT AND CEO) on 2026‑09‑24.
| 2026-09-24 | Love Douglas | PRESIDENT AND CEO | 26,065 0.016% | $3.83 | $99,829 | +5.39% | ||
| 2026-05-28 | Satter Muneer A | director | 613,497 0.5168% | $5.41 | $3.32M | -7.45% | ||
| 2026-05-11 | Carson William H. | director | 8,000 0.0068% | $5.78 | $46,240 | -11.09% | ||
| 2026-04-10 | Carson William H. | director | 8,000 0.0068% | $6.20 | $49,600 | -10.94% | ||
| 2026-03-10 | Carson William H. | director | 8,000 0.0068% | $5.67 | $45,360 | -13.49% | ||
| 2026-03-02 | Sale | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 4,339 0.0035% | $5.42 | $23,517 | -4.35% | |
| 2026-03-02 | Sale | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | 5,894 0.0048% | $5.43 | $32,004 | -4.35% | |
| 2026-03-02 | Sale | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 5,565 0.0045% | $5.42 | $30,162 | -4.35% | |
| 2026-03-02 | Sale | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 5,566 0.0045% | $5.42 | $30,168 | -4.35% | |
| 2026-03-02 | Sale | Dananberg Jamie | CHIEF MEDICAL OFFICER | 5,820 0.0047% | $5.43 | $31,603 | -4.35% | |
| 2026-02-18 | Sale | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 6,225 0.0052% | $5.10 | $31,748 | +4.15% | |
| 2026-02-18 | Sale | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | 5,290 0.0045% | $5.10 | $26,979 | +4.15% | |
| 2026-02-18 | Sale | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 7,851 0.0066% | $5.11 | $40,119 | +4.15% | |
| 2026-02-18 | Sale | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 7,857 0.0066% | $5.11 | $40,149 | +4.15% | |
| 2026-02-18 | Sale | Dananberg Jamie | CHIEF MEDICAL OFFICER | 5,290 0.0045% | $5.10 | $26,979 | +4.15% | |
| 2025-12-30 | Carson William H. | director | 4,115 0.0034% | $5.02 | $20,657 | +5.16% | ||
| 2025-12-01 | Carson William H. | director | 4,115 0.0037% | $4.47 | $18,394 | +27.12% | ||
| 2025-12-01 | Choi Jung | director | 33,000 0.028% | $4.19 | $138,270 | +27.12% | ||
| 2025-11-21 | Satter Muneer A | director | 422,613 0.3542% | $4.28 | $1.81M | +22.95% | ||
| 2025-11-20 | Satter Muneer A | director | 400,000 0.3509% | $4.48 | $1.79M | +22.83% |
| Satter Muneer A | director | 10342134 6.3122% | $43.33M | 9 | 0 | +2.91% |
| Love Douglas | PRESIDENT AND CEO | 390476 0.2383% | $1.64M | 2 | 10 | +135.71% |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 170700 0.1042% | $715,233.00 | 1 | 14 | +33.07% |
| Carson William H. | director | 78405 0.0479% | $328,516.95 | 18 | 0 | +23.27% |
| Choi Jung | director | 33000 0.0201% | $138,270.00 | 1 | 0 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5701926 3.4801% | $23.89M | 2 | 0 | +48.68% |
| Clarus Lifesciences III, L.P. | 10 percent owner | 2730635 1.6666% | $11.44M | 1 | 0 | +33.07% |
| Flynn James E | 10 percent owner | 808914 0.4937% | $3.39M | 1 | 0 | +33.07% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
Annexon, Inc. (ANNX) | $59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 114 | +98.28% | 45M | +44.06% |
| Decreased Positions | 46 | -39.66% | 9M | -8.51% |
| New Positions | 42 | New | 13M | New |
| Sold Out Positions | 17 | Sold Out | 4M | Sold Out |
| Total Postitions | 184 | +58.62% | 137M | +35.55% |
| Fmr Llc | $51,971.00 | 7.64% | 11.08M | -5M | -29.4% | 2025-09-30 |
| Blackrock, Inc. | $37,046.00 | 5.45% | 7.9M | -63,360 | -0.8% | 2025-09-30 |
| Bvf Inc/Il | $32,830.00 | 4.83% | 7M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $29,550.00 | 4.35% | 6.3M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $27,367.00 | 4.02% | 5.84M | +469,073 | +8.74% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $24,618.00 | 3.62% | 5.25M | 0 | 0% | 2025-09-30 |
| Bellevue Group Ag | $24,188.00 | 3.56% | 5.16M | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $14,210.00 | 2.09% | 3.03M | +2M | +263.93% | 2025-09-30 |
| Millennium Management Llc | $13,239.00 | 1.95% | 2.82M | +308,689 | +12.28% | 2025-09-30 |
| Woodline Partners Lp | $12,374.00 | 1.82% | 2.64M | +2M | +150.38% | 2025-09-30 |